Cost-effectiveness of a fixed combination of hydroquinone/tretinoin/fluocinolone cream compared with hydroquinone alone in the treatment of melasma

Journal of Drugs in Dermatology, Feb, 2007 by Tania Cestari, Lucie Adjadj, Margaret Hux, Maria Regina Shimizu, Vincent Pierre Rives

4. McDonald RRA, Georgouras KE. Skin disorders in Indo-Chinese immigrants. Med J Aust. 1992;156;12: 852-853.

5. Jimbow M, Jimhovv K. Pigmentary disorders in oriental skin. Clin Dermatol. 1989;7:11-27.

6. Cestari TF, Andrade CB. Hyperpigmentation and melasma: a physiopathologic review for the clinical dermatologist. Cosmet Dermatol. 2005;18:703-706.

7. Wong R, Ellis CN. Physiologic skin changes in pregnancy. J Am Acad Dermatol. 1984;10:929-940.

8. Katsambas A, Antoniou Ch. Melasma. Classification and treatment. J Eur Acad Dermatol Venereol. 1995;4:217-223.

9. Resnik S. Melasma induced by oral contraceptive drugs. JAMA. 1967;199:96-99.

10. Cook H, Gamble C. Satterthwaite PA. Oral contraception by norethynodrel. Am J Obstet Gyne. 1962;82:437-443.

11. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210-216.

12. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997; 133:1433-1440.

13. Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001; 5:105-110.

14. Balkrishnan R, McMichael AJ, Camacho FT, et al. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol. 2003;149:572-577.

15. Rendon M, Bemeburg M, Arellano 1, Picardo M. Treatment of Melasma. J Am Acad Dermatol. 2006;54(5 suppl 2):S272-81.

16. Sanchez JL, Vasquez M. A hydroquinone solution in the treatment of melasma. Int J Dermatol. 1982;2:55-58.

17. Griffiths CE, Finkel JL, Ditre CM, Hamilton TA, Ellis CN, Voorhees JJ. Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trial. Br J Dermatol. 1993; 129: 415-421.

18. Taylor SC, Torok H, Jones T, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis. 2003;72:67-72.

19. Cestari T, Hassun K, Sittart A, de Lourdes Viegas M. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma. J Cosmet Dermatol. (Accepted for publication)

20. Menter A. Rationale for the use of topical corticosteroids in melasma. J Drugs Dermatol. 2004;3:169-174-

21. Ellis CN, Reiter KL, Wheeler JR, Fendrick AM. Economic analysis in dermatology. J Am Acad Dermatol. 2002;46:271-283.

22. Lambert J. Cost-effectiveness of treatments in psoriasis. J Dermatolog Treat. 1999;10 (suppl):S9-Sl 3.

23. IMS Health dataview; 2004.

24. Arenas-Guzman R, Tosti A, Hay R, Haneke E. Pharmacoeconomics--an aid to better decision-making. J Eur Acad Dermatol Venereol. 2005; 19(suppl):34-39.

25. Ellis CN, Reiter KL, Wheeler JR, Fendrick AM. Economic analysis in dermatology. J Am Acad Dermatol. 2002;46:271-283.

26. Peeters P, Ortonne JP, Sitbon R, Guignard E. Cost-effectiveness of once-daily treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of psoriasis vulgaris. Dermatology. 2005;211:139-145.